Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

NHS England appoints Sir James Mackey as CEO

Mackey is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust

- PMLiVE

DE&I in clinical trials: the role of health literacy and AI

By Claire Paling and Rosamund Round

- PMLiVE

FDA approves Mirum’s Ctexli as first treatment for rare lipid storage disease CTX

The progressive genetic disorder affects up to 2,000 people in the US

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Recce’s topical gel shows promise in acute bacterial skin and skin structure infections

ABSSSIs, including diabetic foot infections, are considered to be a significant healthcare concern

- PMLiVE

Porterhouse Medical appoints Michael Tague as president of Porterhouse Medical US

Tague most recently served as head of North America at CMC Connect

- PMLiVE

Class is the missing link in health equity strategies

By Jenny Carrington-Elson

- PMLiVE

Getting to know eLearning

At LOVELIVE we have a wealth of skills and experience when it comes to designing and producing engaging eLearning tools. User experience is key, so we combine easy to navigate...

LOVELIVE

- PMLiVE

PMLiVE’s Top Pharma list is live

The data was provided by GlobalData, a data analysis and consulting company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links